- Home
- ABVC vs KRRO Comparison
ABVC vs KRRO Comparison
Compare ABVC & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABVC | KRRO |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.5M | 58.6M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | ABVC | KRRO |
|---|---|---|
| Price | $2.04 | $11.69 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $74.17 |
| AVG Volume (30 Days) | 55.6K | ★ 221.9K |
| Earning Date | 11-03-2025 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $797,916.00 | ★ $7,371,000.00 |
| Revenue This Year | $735.18 | $145.49 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 56.52 | N/A |
| 52 Week Low | $0.40 | $5.20 |
| 52 Week High | $5.48 | $55.89 |
Technical Indicators
Market Signals| Indicator | ABVC | KRRO |
|---|---|---|
| Relative Strength Index (RSI) | 40.96 | 67.56 |
| Support Level | $2.00 | $9.88 |
| Resistance Level | $2.20 | $10.93 |
| Average True Range (ATR) | 0.12 | 0.86 |
| MACD | 0.00 | 0.48 |
| Stochastic Oscillator | 22.86 | 83.42 |
Price Performance
Historical ComparisonAbout ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.
About KRRO Korro Bio Inc.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.